AstraZeneca Wins China Approval of Heart Drug
November 30, 2012 at 05:01 AM EST
AstraZeneca was given SFDA approval for Brilinta, a drug that helps prevent blood clots, for patients with acute coronary syndrome. Brilinta was approved in the EU in 2010 and the US in 2011. Although it was more effective than industry-standard Plavix, Brilinta has not met its revenue expectations. In the west, Plavix is now available in generic form, making it even more difficult for AstraZeneca to make inroads. More details.... Stock Symbol: (NYSE: AZN) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});